Madeline Lemke1,2, Kaitlyn Beyfuss1, Julie Hallet2, Natalie G Coburn1,2, Calvin H L Law1,2, Paul J Karanicolas3,4. 1. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 2. Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, T2-016, Toronto, ON, M4N 3M5, Canada. 3. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. paul.karanicolas@sunnybrook.ca. 4. Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, T2-016, Toronto, ON, M4N 3M5, Canada. paul.karanicolas@sunnybrook.ca.
Abstract
BACKGROUND: Guidelines recommend 28 days venous thromboembolism (VTE) prophylaxis with low-molecular-weight heparin (LMWH) following major abdominal surgery for cancer. Overall adherence with these recommendations is poor, but little is known about feasibility and tolerability from a patient perspective. METHODS: An institution-wide policy for routine administration of 28 days of post-operative LMWH following major hepatic or pancreatic resection for cancer was implemented in April 2013. Patients having surgery from July 2013 to June 2015 were approached to participate in an interview examining adherence and experience with extended duration LMWH. RESULTS: There were 100 patients included, with 81.4 % reporting perfect adherence with the regimen. The most frequent reasons for non-adherence were that a healthcare provider stopped the regimen or because of poor experience with injections. Most patients were able to correctly recall the reason for being prescribed LMWH (82.6 %), and 78.4 % of patients performed all injections themselves. Over half the patients (55.7 %) did not find the injections bothersome. CONCLUSION: Patients reported high adherence and a manageable experience with post-operative extended-duration LMWH in an ambulatory setting following liver or pancreas resection. These findings suggest that patient adherence is not a major contributor to poor compliance with VTE prophylaxis guidelines.
BACKGROUND: Guidelines recommend 28 days venous thromboembolism (VTE) prophylaxis with low-molecular-weight heparin (LMWH) following major abdominal surgery for cancer. Overall adherence with these recommendations is poor, but little is known about feasibility and tolerability from a patient perspective. METHODS: An institution-wide policy for routine administration of 28 days of post-operative LMWH following major hepatic or pancreatic resection for cancer was implemented in April 2013. Patients having surgery from July 2013 to June 2015 were approached to participate in an interview examining adherence and experience with extended duration LMWH. RESULTS: There were 100 patients included, with 81.4 % reporting perfect adherence with the regimen. The most frequent reasons for non-adherence were that a healthcare provider stopped the regimen or because of poor experience with injections. Most patients were able to correctly recall the reason for being prescribed LMWH (82.6 %), and 78.4 % of patients performed all injections themselves. Over half the patients (55.7 %) did not find the injections bothersome. CONCLUSION:Patients reported high adherence and a manageable experience with post-operative extended-duration LMWH in an ambulatory setting following liver or pancreas resection. These findings suggest that patient adherence is not a major contributor to poor compliance with VTE prophylaxis guidelines.
Authors: Kevin P Cohoon; Cynthia L Leibson; Jeanine E Ransom; Aneel A Ashrani; Myung S Park; Tanya M Petterson; Kirsten Hall Long; Kent R Bailey; John A Heit Journal: Surgery Date: 2015-01-26 Impact factor: 3.982
Authors: Christine Klimowicz White; Jessica Langholtz; Zackory T Burns; Susan Kruse; Kimberly Sallee; David H Henry Journal: Support Care Cancer Date: 2014-09-27 Impact factor: 3.603
Authors: Aslam Ejaz; Gaya Spolverato; Yuhree Kim; Donald L Lucas; Brandyn Lau; Matthew Weiss; Fabian M Johnston; Marin Kheng; Marian Kheng; Kenzo Hirose; Christopher L Wolfgang; Elliott Haut; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2013-12-13 Impact factor: 3.452
Authors: Ryan S Turley; Srinevas K Reddy; Cynthia K Shortell; Bryan M Clary; John E Scarborough Journal: J Gastrointest Surg Date: 2012-06-30 Impact factor: 3.452
Authors: Robert W Krell; Christopher P Scally; Sandra L Wong; Zaid M Abdelsattar; Nancy J O Birkmeyer; Kelsey Fegan; Joanne Todd; Peter K Henke; Darrell A Campbell; Samantha Hendren Journal: Ann Surg Oncol Date: 2015-11-13 Impact factor: 5.344
Authors: Matthew J Weiss; Yuhree Kim; Aslam Ejaz; Gaya Spolverato; Elliott R Haut; Kenzo Hirose; Christopher L Wolfgang; Michael A Choti; Timothy M Pawlik Journal: HPB (Oxford) Date: 2014-05-28 Impact factor: 3.647
Authors: Igor A Suchkov; Javier Martinez-Gonzalez; Sebastian M Schellong; Toni Garbade; Michela Falciani Journal: Clin Drug Investig Date: 2018-02 Impact factor: 2.859
Authors: M Farzan Rashid; Terri L Jackson; Jheanell A Morgan; Franklin A Dwyer; Beth A Schrope; John A Chabot; Michael D Kluger Journal: J Gastrointest Surg Date: 2018-09-05 Impact factor: 3.452
Authors: M José Martínez-Zapata; Alexander G Mathioudakis; Shaker A Mousa; Rupert Bauersachs Journal: Clin Appl Thromb Hemost Date: 2017-03-14 Impact factor: 2.389